Century Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
IPSC$1.81+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except share amounts)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · | |||||||||||||||||
| · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · Additional · · · · · Other · · Total | |||||||||||||||||
| · · Common Stock · · Paid-in · · Accumulated · · Comprehensive · · Stockholders’ | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Deficit · · Gain (Loss) · · Equity | |||||||||||||||||
| Balance, December 31, 2023 | | 60,335,701 | | $6 | | $840,407 | | $(655,771) | | | 108 | | $184,750 | ||||
| Issuance of common stock upon the exercise of stock options and 2021 ESPP | | 635,471 | | | 1 | | | 772 | | | — | | | — | | | 773 |
| Vesting of restricted stock | | 24,734 | | | — | | | — | | | — | | | — | | | — |
| Vesting of early exercise stock options | | 107,959 | | | — | | | 558 | | | — | | | — | | | 558 |
| Vesting of restricted stock units | | 1,033,315 | | | — | | | (635) | | | — | | | — | | | (635) |
| Issuance of common stock in connection with the acquisition of Clade (Note 3) | | 3,741,646 | | | — | | | 15,154 | | | — | | | — | | | 15,154 |
| Issuance of common stock via ATM, net of underwriting discounts and commissions and other issuance costs | | 4,084,502 | | | — | | | 17,829 | | | — | | | — | | | 17,829 |
| Issuance of common stock via PIPE, net of underwriting discounts and commissions and other issuance costs | | 15,873,101 | | | 2 | | | 56,593 | | | — | | | — | | | 56,595 |
| Unrealized gain on investments | | — | | | — | | | — | | | — | | | 153 | | | 153 |
| Foreign currency translation | | — | | | — | | | — | | | — | | | 63 | | | 63 |
| Stock based compensation | | — | | | — | | | 12,688 | | | — | | | — | | | 12,688 |
| Net loss | | — | | | — | | | — | | | (126,566) | | | — | | | (126,566) |
| Balance, December 31, 2024 | | 85,836,429 | | $9 | | $943,366 | | $(782,337) | | $324 | | $161,362 | |||||
| Issuance of common stock upon the exercise of stock options and 2021 ESPP | | 282,261 | | | — | | | 173 | | | — | | | — | | | 173 |
| Vesting of restricted stock | | 24,734 | | | — | | | — | | | — | | | — | | | — |
| Vesting of early exercise stock options | | 11,321 | | | — | | | 82 | | | — | | | — | | | 82 |
| Vesting of restricted stock units | | 580,223 | | | — | | | (94) | | | — | | | — | | | (94) |
| Issuance of common stock in connection with the acquisition of Clade (Note 3) | | 784,128 | | | — | | | 447 | | | — | | | — | | | 447 |
| Unrealized loss on investments | | — | | | — | | | — | | | — | | | (294) | | | (294) |
| Stock based compensation | | — | | | — | | | 6,840 | | | — | | | — | | | 6,840 |
| Net loss | | — | | | — | | | — | | | (9,580) | | | — | | | (9,580) |
| Balance, December 31, 2025 | | 87,519,096 | | $9 | | $950,814 | | $(791,917) | | $30 | | $158,936 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.